256 related articles for article (PubMed ID: 19133704)
1. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.
Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
Clin Drug Investig; 2009; 29(2):87-100. PubMed ID: 19133704
[TBL] [Abstract][Full Text] [Related]
2. Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.
Darwish M; Kirby M; Hellriegel ET; Yang R; Robertson P
Drugs Aging; 2011 Feb; 28(2):139-50. PubMed ID: 21275439
[TBL] [Abstract][Full Text] [Related]
3. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.
Darwish M; Kirby M; Hellriegel ET; Robertson P
Clin Drug Investig; 2009; 29(9):613-23. PubMed ID: 19663523
[TBL] [Abstract][Full Text] [Related]
4. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects.
Darwish M; Kirby M; Hellriegel ET
Clin Drug Investig; 2009; 29(9):601-12. PubMed ID: 19663522
[TBL] [Abstract][Full Text] [Related]
5. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss.
Dinges DF; Arora S; Darwish M; Niebler GE
Curr Med Res Opin; 2006 Jan; 22(1):159-67. PubMed ID: 16393442
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites.
Willavize S; Fiedler-Kelly J; Ludwig E; Guan L
J Clin Pharmacol; 2017 Feb; 57(2):255-265. PubMed ID: 27436172
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
Wong YN; Simcoe D; Hartman LN; Laughton WB; King SP; McCormick GC; Grebow PE
J Clin Pharmacol; 1999 Jan; 39(1):30-40. PubMed ID: 9987698
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study.
Darwish M; Kirby M; D'Andrea DM; Yang R; Hellriegel ET; Robertson P
Clin Ther; 2010 Nov; 32(12):2074-87. PubMed ID: 21118743
[TBL] [Abstract][Full Text] [Related]
10. Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships.
Darwish M; Bond M; Ezzet F
J Clin Pharmacol; 2012 Sep; 52(9):1328-42. PubMed ID: 22039290
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression.
Niemegeers P; Maudens KE; Morrens M; Patteet L; Joos L; Neels H; Sabbe BG
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1189-97. PubMed ID: 22803602
[TBL] [Abstract][Full Text] [Related]
12. Armodafinil for excessive daytime sleepiness.
Nishino S; Okuro M
Drugs Today (Barc); 2008 Jun; 44(6):395-414. PubMed ID: 18596995
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period.
Schwartz JR; Khan A; McCall WV; Weintraub J; Tiller J
J Clin Sleep Med; 2010 Oct; 6(5):450-7. PubMed ID: 20957845
[TBL] [Abstract][Full Text] [Related]
14. Armodafinil in the treatment of excessive sleepiness.
Bogan RK
Expert Opin Pharmacother; 2010 Apr; 11(6):993-1002. PubMed ID: 20307223
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects.
Xu P; Li HD; Zhang BK; Xiao YW; Yuan HY; Zhu YG
J Clin Pharm Ther; 2008 Aug; 33(4):429-37. PubMed ID: 18613861
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults.
Darwish M; Bond M; Yang R; Hellriegel ET; Robertson P
Clin Drug Investig; 2014 Oct; 34(10):691-9. PubMed ID: 25047407
[TBL] [Abstract][Full Text] [Related]
17. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study.
Black JE; Hull SG; Tiller J; Yang R; Harsh JR
J Clin Sleep Med; 2010 Oct; 6(5):458-66. PubMed ID: 20957846
[TBL] [Abstract][Full Text] [Related]
18. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects.
Wong YN; King SP; Simcoe D; Gorman S; Laughton W; McCormick GC; Grebow P
J Clin Pharmacol; 1999 Mar; 39(3):281-8. PubMed ID: 10073328
[TBL] [Abstract][Full Text] [Related]
19. Armodafinil: a new treatment for excessive sleepiness.
Lankford DA
Expert Opin Investig Drugs; 2008 Apr; 17(4):565-73. PubMed ID: 18363520
[TBL] [Abstract][Full Text] [Related]
20. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study.
Czeisler CA; Walsh JK; Wesnes KA; Arora S; Roth T
Mayo Clin Proc; 2009 Nov; 84(11):958-72. PubMed ID: 19880686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
